Literature DB >> 10601246

Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site.

C J Loland1, L Norregaard, U Gether.   

Abstract

Recently, we have described a distance constraint in the unknown tertiary structure of the human dopamine transporter (hDAT) by identification of two histidines, His(193) in the second extracellular loop and His(375) at the top of transmembrane (TM) 7, that form two coordinates in an endogenous, high affinity Zn(2+)-binding site. To achieve further insight into the tertiary organization of hDAT, we set out to identify additional residues involved in Zn(2+) binding and subsequently to engineer artificial Zn(2+)-binding sites. Ten aspartic acids and glutamic acids, predicted to be on the extracellular side, were mutated to asparagine and glutamine, respectively. Mutation of Glu(396) (E396Q) at the top of TM 8 increased the IC(50) value for Zn(2+) inhibition of [(3)H]dopamine uptake from 1.1 to 530 microM and eliminated Zn(2+)-induced potentiation of [(3)H]WIN 35,428 binding. These data suggest that Glu(396) is involved in Zn(2+) binding to hDAT. Importantly, Zn(2+) sensitivity was preserved following substitution of Glu(396) with histidine, indicating that the effect of mutating Glu(396) is not an indirect effect because of the removal of a negatively charged residue. The common participation of Glu(396), His(193), and His(375) in binding the small Zn(2+) ion implies their proximity in the unknown tertiary structure of hDAT. The close association between TM 7 and 8 was further established by engineering of a Zn(2+)-binding site between His(375) and a cysteine inserted in position 400 in TM 8. Summarized, our data define an important set of proximity relationships in hDAT that should prove an important template for further exploring the molecular architecture of Na(+)/Cl(-)-dependent neurotransmitter transporters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601246     DOI: 10.1074/jbc.274.52.36928

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Zinc inhibition of gamma-aminobutyric acid transporter 4 (GAT4) reveals a link between excitatory and inhibitory neurotransmission.

Authors:  Einav Cohen-Kfir; William Lee; Sepehr Eskandari; Nathan Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-13       Impact factor: 11.205

Review 2.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.

Authors:  Claus Juul Loland; Lene Norregaard; Thomas Litman; Ulrik Gether
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

4.  Taurine and zinc modulate outgrowth from goldfish retinal explants.

Authors:  S Nusetti; F Obregón; M Quintal; Z Benzo; L Lima
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

5.  Molecular Mechanism of Dopamine Transport by Human Dopamine Transporter.

Authors:  Mary Hongying Cheng; Ivet Bahar
Journal:  Structure       Date:  2015-10-15       Impact factor: 5.006

Review 6.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

7.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

8.  The N terminus of monoamine transporters is a lever required for the action of amphetamines.

Authors:  Sonja Sucic; Stefan Dallinger; Barbara Zdrazil; René Weissensteiner; Trine N Jørgensen; Marion Holy; Oliver Kudlacek; Stefan Seidel; Joo Hwan Cha; Ulrik Gether; Amy H Newman; Gerhard F Ecker; Michael Freissmuth; Harald H Sitte
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

9.  Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.

Authors:  Yvette Dehnes; Jufang Shan; Thijs Beuming; Lei Shi; Harel Weinstein; Jonathan A Javitch
Journal:  Neurochem Int       Date:  2014-02-24       Impact factor: 3.921

10.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.